



## DISCOVERY LABORATORIES, INC.

### **Discovery Laboratories to Present at the 22<sup>nd</sup> Annual JP Morgan Healthcare Conference**

*Presentation on Thursday, January 15, at 8:30 am Standard Pacific Time*

**Doylestown, PA — January 5, 2004 — Discovery Laboratories, Inc. (Nasdaq: DSCO)**, a biopharmaceutical company developing its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory diseases, today announced that Robert J. Capetola, Ph.D., President and Chief Executive Officer of Discovery, will provide an update on the company's progress during the 22<sup>nd</sup> Annual JP Morgan Healthcare Conference in San Francisco. The conference will be simultaneously webcast over the Internet.

The JP Morgan Healthcare Conference will provide an opportunity to hear from over 260 public and private companies in the life sciences, medical technology and healthcare services sectors.

**Dr. Capetola is scheduled to speak on January 15, 2004, at approximately 8:30 am Standard Pacific Time.** Interested investors and other parties can access the live audio webcast of the presentation by going to <http://equityconferences.jpmorgan.com> or Discovery Laboratories' web site, [www.discoverylabs.com](http://www.discoverylabs.com). A replay of the audio webcast will be available on Discovery Laboratories' website for thirty days.

#### **About Discovery Laboratories**

Discovery Laboratories, Inc. is a biopharmaceutical company developing its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory diseases including Respiratory Distress Syndromes in infants and adults, Acute Lung Injury, asthma, Chronic Obstructive Pulmonary Disease and upper airway disorders. Surfactants are compositions produced naturally in the lungs and essential for breathing. Discovery's technology produces an engineered version of natural human lung surfactant that is designed to closely mimic the essential properties of human lung surfactant. Discovery believes that through its technology, pulmonary surfactants have the potential, for the first time, to be developed into a series of respiratory therapies for critical care and other hospitalized patients where there are few or no approved therapies available.

Discovery recently completed two Phase 3 clinical trials of Surfaxin<sup>®</sup>, the Company's lead product, for the treatment of Respiratory Distress Syndrome in premature infants and is preparing to file new drug applications with the United States Food and Drug Administration and other regulatory authorities in the rest of the world. Discovery's Surfactant Replacement Therapy is also in a Phase 2 clinical trial for Acute Respiratory Distress Syndrome in adults, a

Phase 3 and a Phase 2 clinical trial for Meconium Aspiration Syndrome in full-term infants, and a Phase 1b clinical trial for asthma.

More information about Discovery Laboratories is available on the Company's Web site at [www.discoverylabs.com](http://www.discoverylabs.com).

*To the extent that statements in this press release are not strictly historical, including statements as to business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's product development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Among the factors which could affect the company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are the risk that financial conditions may change, risks relating to the progress of the company's research and development, the risk that the Company will not be able to raise additional capital or enter into additional collaboration agreements (including strategic alliances for our aerosol and Surfactant Replacement Therapies), risks relating to the progress of the Company's research and development, risks relating to the ability of the Company's third party contract manufacturers to provide the Company with sufficient amounts of drug products for completion of any of the Company's clinical studies, other risks relating to the lack of sufficient drug product for completion of any of the Company's clinical studies, and risks relating to the development of competing therapies and/or technologies by other companies. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials, even after obtaining promising earlier trial results. Data obtained from tests are susceptible to varying interpretations which may delay, limit or prevent regulatory approval. Those associated risks and others are further described in the company's filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-KSB, 8-K, 10-Q and 10-QSB, and amendments thereto.*

**Company Contacts:**

John G. Cooper, SVP, CFO  
Kori Beer, IR & Communications  
215-340-4699